Daily Stock Pick â€” January 21, 2026

FOLD â€“ Amicus Therapeutics

News: Agreed to be acquired by BioMarin for $14.50/share cash; closing targeted for Q2 2026; strong 2024 growth and 2025 profitability trajectory reduce downside. ([investors.biomarin.com](https://investors.biomarin.com/news/news-details/2025/BioMarin-to-Acquire-Amicus-Therapeutics-for-4-8-Billion-Expanding-Position-as-a-Leader-in-Rare-Diseases-Accelerating-Revenue-Growth-and-Strengthening-Financial-Outlook/default.aspx?utm_source=openai))

Score (0â€“1000): "(BrainScore 520 + EV/risk adjustment +100) = 620"

ADVICE: "Buy"

Certainty: "72%"

Forecast image URL: "https://stockscan.io/stocks/FOLD/forecast"

Verifier note: "Merger-arb setup with defined cash takeout, minimal antitrust risk; fundamentals solid (2024 rev +33% to ~$528M; path to GAAP profitability; resolved Galafold patent risk), and adequate liquidityâ€”supporting limited downside over 6 months. Sources: investors.biomarin.com (deal terms/closing window), ir.amicusrx.com (FY2024 results/guidance)." ([investors.biomarin.com](https://investors.biomarin.com/news/news-details/2025/BioMarin-to-Acquire-Amicus-Therapeutics-for-4-8-Billion-Expanding-Position-as-a-Leader-in-Rare-Diseases-Accelerating-Revenue-Growth-and-Strengthening-Financial-Outlook/default.aspx?utm_source=openai))

---
**Legend**
ğŸŸ¢ğŸŸ¢ğŸŸ¢ **Ultra Strong Buy** â€” Score > 800 â†’ â€œGuaranteed high returnâ€
ğŸŸ¢ **Strong Buy** â€” Score > 700 â†’ â€œAmazing Chancesâ€
ğŸŸ¡ **Buy** â€” Score â‰ˆ 600 â†’ â€œGreat Chancesâ€
ğŸ”´ **Ignore** â€” Score < 599 â†’ â€œIgnoreâ€

